Globe Newswire

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.

“These... (continue reading...)

LONDON, June 03, 2024 (GLOBE NEWSWIRE) -- Pixalate, the global market-leading ad fraud protection, privacy, and compliance analytics platform, today launched the world’s first Website Publisher Trust Indexes, a global approach to quality measurement and monthly rankings of the world’s websites, designed to bring unprecedented transparency to the programmatic advertising ecosystem. Pixalate uses proprietary algorithms to measure a range of quality metrics,... (continue reading...)

Laurel, Maryland, June 03, 2024 (GLOBE NEWSWIRE) -- For the sixth consecutive year, Tower Federal Credit Union has been named a “great workplace” by the independent analysts at Great Place to Work® (GPTW). Rick Stafford, Tower’s President and CEO, credits Tower’s exceptional team of employees and the credit union’s service-driven, people-oriented culture as the reason for the recognition.

“Our Great Place to Work recognition is especially meaningful... (continue reading...)

LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hertz Global Holdings, Inc. (“Hertz” or “the Company”) (NASDAQ: HTZ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between April... (continue reading...)

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte’s (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The study's positive outcomes highlight new... (continue reading...)